The minimal important difference for the St George's Respiratory Questionnaire in patients with severe COPD

European Respiratory Journal

Volumn 46, Issue 6, 2015, Pages 1598-1604

  Welling, Jorrit B A ^a   Hartman, Jorine E ^a   Ten Hacken, Nick H T ^a   Klooster, Karin ^a   Slebos, Dirk Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG RESECTION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRE; RESIDUAL VOLUME; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGED; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESIDUAL VOLUME; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84946759726     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00535-2015     Document Type: Article

References (25)

1. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85: (Suppl. B), 25-31; discussion 33-37.
2. Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007; 7: 541-546.
3. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
4. Slebos DJ, Klooster K, Ernst A, et al. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. Chest 2012; 142: 574-582.
5. Klooster K, Ten Hacken NH, Slebos DJ. The lung volume reduction coil for the treatment of emphysema: a new therapy in development. Expert Rev Med Devices 2014; 11: 481-489.
6. Herth FJ, Eberhardt R, Gompelmann D, et al. Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. Eur Respir J 2013; 41: 302-308.
7. Shah PL, Slebos DJ, Cardoso PF, et al. Bronchoscopic lung-volume reduction with Exhale Airway Stents for Emphysema (EASE trial): randomised, sham-controlled, multicentre trial. Lancet 2011; 378: 997-1005.
8. Deslee G, Klooster K, Hetzel M, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax 2014; 69: 980-986.
9. Klooster K, Ten Hacken NH, Franz I, et al. Lung volume reduction coil treatment in chronic obstructive pulmonary disease patients with homogeneous emphysema: a prospective feasibility trial. Respiration 2014; 88: 116-125.
10. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124.
11. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011; 37: 784-790.
12. Hartman JE, Ten Hacken NH, Klooster K, et al. The minimal important difference for residual volume in patients with severe emphysema. Eur Respir J 2012; 40: 1137-1141.
13. Altenburg WA, Duiverman ML, Ten Hacken NH, et al. Changes in the endurance shuttle walk test in COPD patients with chronic respiratory failure after pulmonary rehabilitation: the minimal important difference obtained with anchor- and distribution-based method. Respir Res 2015; 16: 27.
14. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-109.
15. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
17. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
19. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 365: 775-789.
20. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
21. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250-255.
22. Troosters T. How important is a minimal difference? Eur Respir J 2011; 37: 755-756.
23. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.
24. Holland AE, Hill CJ, Rasekaba T, et al. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010; 91: 221-225.
25. Iftikhar IH, McGuire FR, Musani AI. Efficacy of bronchoscopic lung volume reduction: a meta-analysis. Int J Chron Obstruct Pulmon Dis 2014; 9: 481-491.